A phase I trial to investigate safety, tolerability and pharmacokinetics of RQ-00310941 in healthy subjects, and to evaluate how food and gender differences affect these profiles
Phase of Trial: Phase I
Latest Information Update: 20 Apr 2016
At a glance
- Drugs RQ 00310941 (Primary)
- Indications Irritable bowel syndrome
- Focus Adverse reactions; Pharmacokinetics
- 20 Apr 2016 According to RaQualia Pharma media release, this study will be followed by examining the effects of RQ-00310941 on patients with abdominal symptoms.
- 20 Apr 2016 Status changed from not yet recruiting to recruiting, as reported by RaQualia Pharma media release.
- 04 Jun 2015 New trial record